Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

NCT04067115 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.

NCT NCT04067115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04067115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Phase
Phase 1/2
Overall status
Completed
Start date
January 5, 2021
Completion date
April 24, 2025
Enrollment
37 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma